-
公开(公告)号：US09701664B2
公开(公告)日：2017-07-11
申请号：US15026911
申请日：2014-10-03
Applicant: Cancer Research Technology Limited
Inventor： Keith Jones , Carl Rye , Nicola Chessum , Matthew Cheeseman , Adele E. Pasqua , Kurt G. Pike , Paul F. Faulder
IPC: C07D405/12 , C07D405/14 , C07D319/18 , C07D407/12 , C07D471/04 , C07D491/056 , C07D409/12 , C07D417/12 , C07D417/14 , C07D487/08
CPC classification number: C07D405/12 , C07D319/18 , C07D405/14 , C07D407/12 , C07D409/12 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/08 , C07D491/056
Abstract: The present invention relates to compounds of formula I as defined herein. The compounds of the present invention are inhibitors of heat shock factor 1 (HSF1). In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.
-
公开(公告)号：US09683032B2
公开(公告)日：2017-06-20
申请号：US14439411
申请日：2013-10-29
Applicant: Cancer Research Technology Limited
Inventor： Jorg Klingelhöfer , Noona Ambartsumian , Mariam Grigorian , Eugene Lukanidin
IPC: C07K16/18 , C07K16/30 , A61K39/395 , A61K45/06 , G01N33/574 , A61K39/00 , A61N5/10
CPC classification number: C07K16/18 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61N2005/1098 , C07K16/30 , C07K2317/24 , C07K2317/30 , C07K2317/33 , C07K2317/34 , C07K2317/76 , C07K2317/92 , G01N33/57415 , G01N2333/4727
Abstract: Anti-S100A4 antibody molecules that are capable of inhibiting the biological activity of S100A4 in promoting tumor progression and/or in inducing tumor metastasis are described. The antibody molecules are also useful in the treatment of inflammatory conditions. The properties of the antibodies are demonstrated using in vitro and in vivo assays.
-
公开(公告)号：US20170152254A1
公开(公告)日：2017-06-01
申请号：US15363018
申请日：2016-11-29
Applicant: AstraZeneca AB , Cancer Research Technology Limited
Inventor： Johannes Wilhelmus Maria Nissink , Maurice Raymond Verschoyle Finlay , Mark David Charles , Matt Wood
IPC: C07D417/14
CPC classification number: C07D417/14 , A61K31/501 , A61K31/53
Abstract: A compound of Formula (I): or a pharmaceutically acceptable salt thereof, where: Q can be 5-methylpyridazin-3-yl, 5-chloropyridazin-3-yl, 6-methylpyridazin-3-yl, or 6-fluoropyridazin-3-yl; R can be hydrogen, fluoro, or methoxy; R1 can be hydrogen, methoxy, difluoromethoxy, or trifluoromethoxy; and R2 can be methyl or ethyl. The compound of formula (I) can inhibit glutaminase, e.g., GLS1.
-
公开(公告)号：US20170107222A1
公开(公告)日：2017-04-20
申请号：US15129338
申请日：2015-03-10
Applicant: MERCK PATENT GMBH , CANCER RESEARCH TECHNOLOGY LIMITED
Inventor： Kai SCHIEMANN , Frank STIEBER , Michel CALDERINI , Julian BLAGG , Aurelie MALLINGER , Dennis WAALBOER , Christian RINK , Simon Ross CRUMPLER
IPC: C07D471/20 , C07D498/10 , C07D401/14 , C07D417/14 , C07D519/00 , A61K31/444 , A61K31/499 , A61K31/5377 , A61K31/4709 , A61K31/4725 , C07D471/10 , A61K45/06
CPC classification number: C07D471/20 , A61K31/444 , A61K31/4709 , A61K31/4725 , A61K31/499 , A61K31/5377 , A61K45/06 , C07D401/14 , C07D417/14 , C07D471/10 , C07D498/10 , C07D519/00
Abstract: The invention provides novel substituted pyridyl piperidine compounds according to Formula (I) which are Wnt pathway inhibitors, their manufacture and use for the treatment of hyperproliferative diseases such as cancer, inflammatory or degenerative diseases.
-
公开(公告)号：US09447092B2
公开(公告)日：2016-09-20
申请号：US14409042
申请日：2013-06-21
Applicant: CANCER RESEARCH TECHNOLOGY LIMITED
Inventor： Julian Blagg , Vassilios Bavetsias , Andrew S. Moore , Spyridon Linardopoulos
IPC: C07D471/04 , A61K31/496 , C07D471/06
CPC classification number: C07D471/04 , C07D471/06
Abstract: The present invention relates to compounds of formula I: wherein R1 and R2 are as defined herein, or a pharmaceutically acceptable salt or solvate thereof. The compounds of formula I are inhibitors of aurora kinase and/or FLT3. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which aurora kinase and/or FLT3 activity is implicated.
-
Patent Agency Ranking
公开(公告)号：US20160223442A1
公开(公告)日：2016-08-04
申请号：US15021470
申请日：2014-09-12
Applicant: CANCER RESEARCH TECHNOLOGY LIMITED
Inventor： Per GULDBERG , Kenneth Eric STEVEN
CPC classification number: G01N1/4077 , A61B10/007 , A61B10/0096 , B01D27/08 , B01L3/502 , B01L2200/04 , B01L2200/0631 , B01L2300/041 , B01L2300/0681 , B01L2300/0832 , B01L2300/087 , B01L2300/12 , B01L2400/0478 , B01L2400/0487 , C12N15/1017 , C12Q1/6806 , C12Q1/6886 , C12Q2600/154 , C12Q2600/158 , G01N2001/4088
Abstract: The present invention relates to biological fluid filtration assemblies and to methods of using such assemblies. The biological fluid filtration assembly has a filtration device for filtering a biological fluid sample and a storage unit, the storage unit having a body configured to engage with a removable filter cartridge of the device such that, when engaged, the filter of the filter cartridge is sealed within the body of the storage unit.
Abstract translation: 本发明涉及生物流体过滤组件以及使用这种组件的方法。 生物流体过滤组件具有用于过滤生物流体样品和存储单元的过滤装置，所述存储单元具有构造成与装置的可移除过滤器滤芯接合的主体，使得当接合时，过滤器滤芯的过滤器 密封在存储单元的主体内。
-
公开(公告)号：US20160222009A1
公开(公告)日：2016-08-04
申请号：US15091887
申请日：2016-04-06
Applicant: Cancer Research Technology Limited
Inventor： Swen Hoelder , Julian Blagg , Savade Solanki , Hannah Woodward , Sebastien Naud , Vassilios Bavetsias , Peter Sheldrake , Paolo Innocenti , Kwai-Ming J. Cheung , Butrus Atrash
IPC: C07D471/04 , C07D519/00 , C07D401/04 , C07D405/04 , C07D401/14 , C07D413/14
CPC classification number: C07D471/04 , A61K31/519 , C07D401/04 , C07D401/14 , C07D405/04 , C07D413/14 , C07D519/00
Abstract: The present invention relates to compounds of formula I wherein R1, R4, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.
-
公开(公告)号：US20160220570A1
公开(公告)日：2016-08-04
申请号：US15091980
申请日：2016-04-06
Applicant: Cancer Research Technology Limited
Inventor： Swen Hoelder , Julian Blagg , Savade Solanki , Hannah Woodward , Sebastien Naud , Vassilios Bavetsias , Peter Sheldrake , Paolo Innocenti , Kwai-Ming J. Cheung , Butrus Atrash
IPC: A61K31/519
CPC classification number: C07D471/04 , A61K31/519 , C07D401/04 , C07D401/14 , C07D405/04 , C07D413/14 , C07D519/00
Abstract: The present invention relates to compounds of formula I wherein R1, R4, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.
-
49.发明申请公开(公告)号：US20160176975A1
公开(公告)日：2016-06-23
申请号：US15040375
申请日：2016-02-10
Applicant: Københavns Universitet , Cancer Research Technology Limited
Inventor： Henrik Clausen , Joy Burchell , Ulla Mandel , Anne Louise Sørensen , Mads Agervig Tarp , Joyce Taylor-Papadimitriou
CPC classification number: C07K16/2896 , A61K39/0011 , A61K47/646 , A61K2039/5154 , A61K2039/5158 , A61K2039/6031 , A61K2039/6037 , A61K2039/6075 , A61K2039/6081 , C07K14/4727 , C07K16/28 , C07K16/30 , C07K16/3092 , C07K2317/14 , C07K2317/34 , C07K2317/76 , C40B30/04 , C40B50/06 , G01N33/574 , G01N33/6854 , Y02A50/412
Abstract: The present invention provides a method for inducing a cancer specific immune response against MUC1 using an immunogenic glycopeptide. Other aspects of the invention are a pharmaceutical composition comprising the immunogenic glycopeptide and a cancer vaccine comprising the immunogenic glycopeptide. Another aspect is an antibody generated using the immunogenic glycopeptide and the use of said antibody in therapy and diagnosis.
-
公开(公告)号：US09358222B2
公开(公告)日：2016-06-07
申请号：US14085632
申请日：2013-11-20
Applicant: CANCER RESEARCH TECHNOLOGY LIMITED
Inventor： Bernard Thomas Golding , Christiane Riedinger , Roger John Griffin , Ian Robert Hardcastle , Eric Valeur , Anna Frances Watson , Martin Noble
IPC: C07D207/46 , A61K31/4035 , C07D209/48 , C07D401/06 , C07D403/06
CPC classification number: C07D209/49 , A61K31/4035 , A61K31/4402 , A61K45/06 , C07D209/48 , C07D401/06 , C07D403/06
Abstract: A compound of formula (I) or a compound of formula (II) or pharmaceutically acceptable salts thereof, wherein R1-R7 and X are as defined in the description, and the use of these compounds in therapy, in particular in treating cancer or as an inhibitor of the interaction of the MDM2 protein with p53.
-
-
-
-
-
-
-
-
-
Search Results
353
records
(took 0.054 seconds)
